Business Insider

Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization

Business Poised to Continue Driving Revenue and Begin Generating Profits Recro Will Continue to Trade on NASDAQ Under Ticker Symbol “REPH” MALVERN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, ...
Nasdaq

Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility

MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care ...
Nasdaq

Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences

GAINESVILLE, Ga., April 15, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and ...
Business Wire

Recro Gainesville Hires Industry Veteran to Lead Business Development Team

GAINESVILLE, Ga.--(BUSINESS WIRE)--Recro Gainesville, LLC, a wholly owned subsidiary of Recro Pharma, Inc., and a leading provider of solid oral dose manufacturing services for the pharmaceutical ...
Business Insider

Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with ...
Business Wire

Robbins Arroyo LLP: Recro Pharma, Inc. (REPH) Misled Shareholders According to a Recently Filed Class Action

SAN DIEGO & MALVERN, Pa.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Recro Pharma, Inc. (NasdaqCM: REPH) have filed a class action complaint against ...